Regen BioPharma (RGBP) Operating Margin (2016 - 2025)
Regen BioPharma (RGBP) has disclosed Operating Margin for 11 consecutive years, with 207.28% as the latest value for Q3 2025.
- On a quarterly basis, Operating Margin fell 6343.0% to 207.28% in Q3 2025 year-over-year; TTM through Sep 2025 was 143.11%, a 5639.0% increase, with the full-year FY2025 number at 143.11%, up 3326.0% from a year prior.
- Operating Margin was 207.28% for Q3 2025 at Regen BioPharma, down from 69.01% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 6.98% in Q3 2021 to a low of 1466.08% in Q4 2022.
- A 5-year average of 221.98% and a median of 145.49% in 2021 define the central range for Operating Margin.
- Peak YoY movement for Operating Margin: plummeted -112973bps in 2022, then soared 125820bps in 2023.
- Regen BioPharma's Operating Margin stood at 336.35% in 2021, then plummeted by -336bps to 1466.08% in 2022, then soared by 86bps to 207.88% in 2023, then surged by 50bps to 103.92% in 2024, then tumbled by -99bps to 207.28% in 2025.
- Per Business Quant, the three most recent readings for RGBP's Operating Margin are 207.28% (Q3 2025), 69.01% (Q2 2025), and 191.91% (Q1 2025).